tradingkey.logo
tradingkey.logo
Search

Premarket Movers | Denny's Soars 48%; Hims & Hers Gains 3%; Grab Drops 4%; Navitas Sinks 15%; Sarepta Plunges 37%

TigerNov 4, 2025 9:12 AM
facebooktwitterlinkedin
View all comments(0)

Restaurant chain Denny's announced on Monday it would be acquired by a group comprising TGI Fridays-owner TriArtisan Capital Advisors in a $620 million deal, including debt. Denny's shares surged 47.5% in premarket trading on Tuesday.

Exact Sciences shares jumped 4.7% in premarket trading on Tuesday after the cancer screening provider reported third-quarter results that exceeded analyst expectations and raised its full-year outlook.

Hims & Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings. Hims & Hers said it was in active talks with Novo to offer Wegovy injections and, once approved, an oral version through its platform. The shares gained 3.2% in premarket trading on Tuesday.

Baidu shares rose 3% in premarket trading on Tuesday. The rally follows reports that Baidu is accelerating its global autonomous ride-hailing business. As of October 31, its Apollo Go division recorded over 250,000 weekly fully driverless ride-hailing orders—a scale comparable to Waymo’s paid ride volume in the U.S. as of late April this year.

Grab beat analysts' expectations for third-quarter revenue on Monday, supported by robust consumer spending on ride-hailing and food-delivery services as its platform expansion draws in additional users. Third-quarter revenue for Grab's deliveries segment stood at $465 million, compared with estimates of $470 million. The shares dropped 4.3% in premarket trading on Tuesday.

Energy Fuels reported quarterly losses of seven cents per share, which missed the Street estimate for losses of six cents. The shares sank 10.1% in premarket trading.

Navitas Semiconductor shares tumbled 15.4% in premarket trading on Tuesday after the next-generation power semiconductor company reported third-quarter results that missed analyst expectations and announced a strategic pivot away from consumer markets.

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal, sending its shares plummeting 36.9% in premarket trading on Tuesday.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.